You are here

Award Data

For best search results, use the search terms first and then apply the filters

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. A Multi-Sensor Hybrid System for Vehicle Classification of Thirteen Classes

    SBC: Migma Systems Inc.            Topic: 081FH4

    Image processing methods have been studied and implemented for the vehicle classification over the past decades. The most dominant approach is the use of vehicle dimension, which requires complex processes of sensor calibration as the vehicle dimensions shown in the imagery are heavily dependent on the camera’s field of view. In general, video systems have physical disadvantages related to the ...

    SBIR Phase II 2013 Department of Transportation
  2. Web FluidMath

    SBC: FLUIDITY SOFTWARE, INC.            Topic: N/A

    The project team is developing a prototype of WebFluidMath, a software programto support students who are learning basic algebra principles. To use the Web FluidMath program, students will write math expressions and make drawings on the screen of apen-enabled tablet computer (e.g., iPad, Android, Microsoft Surface). The software will recognize the handwritten math formulae and generate solutions ...

    SBIR Phase I 2013 Department of Education
  3. Nomethiazoles Harnessing GABA and NO mimetic activity for Alzheimer's therapy

    SBC: sGC Pharma Inc.            Topic: NIA

    DESCRIPTION (provided by applicant): Alzheimer's disease (AD) occurs in one out of eight Americans of age 65 and affects 43% of the elderly over 85. Current FDA-approved drugs only provide symptomatic relief of AD. There is a pressing need to discover newdisease-modifying medications. AD is multifactorial in origin and progression. A drug attenuating several underlying factors is a preferred ...

    STTR Phase I 2013 Department of Health and Human Services
  4. A Novel Insulin Pathway Agonist for Alzheimer's Disease

    SBC: MEDCHEM PARTNERS LLC            Topic: NIA

    DESCRIPTION (provided by applicant): Even though the association of -amyloid peptide (A ) deposition and Alzheimer's Disease (AD) underpins the major hypothesis for disease progression and possibly causation and several drugs addressing the formation or removal of -amyloid plaques have entered clinical trials, no effective therapy exists to date for AD. This reality calls for new targets th ...

    STTR Phase I 2013 Department of Health and Human Services
  5. A Small Molecule to Activate Tumor Immunity after PLX403 in V600E BRAF Melanoma


    DESCRIPTION (provided by applicant): In the United States, around 76,250 new cases of melanoma and 9,180 melanoma-related deaths are predicted for 2012. With the therapeutic options currently available, metastatic melanoma patients face the bleak prospectof at best, 10 month's survival and a one-in-ten chance of surviving for 10 years. Surgery and radiation therapy are the mainstay of treatme ...

    STTR Phase I 2013 Department of Health and Human Services
  6. High Yield Human Hepatocyte Isolation

    SBC: ORGAN SOLUTIONS, LLC            Topic: NIDDK

    DESCRIPTION (provided by applicant): End-stage liver disease claims about 30,000 lives in the US. Many patients become too ill to tolerate liver transplantation, and even if transplantation were indicated, there is a severe shortage of viable donor organsand only 28% of the wait-listed patients receive transplants. Development and translational studies with novel alternatives to organ transplanta ...

    STTR Phase I 2013 Department of Health and Human Services
  7. Topical Therapeutic to Promote Healing of Chronic Wounds

    SBC: Phoenicia Biosciences, Inc.            Topic: NIGMS

    DESCRIPTION (provided by applicant): Chronic refractory, or non-healing, wounds or ulcerations of the extremities represent a major medical condition affecting millions of patients. A chronic wound is defined as a wound that does not show signs of significant healing, or progresses, after use of topical/surgical treatment measures for six months. Non-healing wounds affect 6.5 million patients, aff ...

    STTR Phase I 2013 Department of Health and Human Services
  8. Pharmacological Targeting of Endothelial Dysfunction in Atherogenesis


    DESCRIPTION (provided by applicant): Pharmacological Targeting of Endothelial Dysfunction in Atherogenesis Cardiovascular disease is the leading cause of morbidity and mortality in the United States and is an emerging epidemic world-wide. In particular, atherosclerosis is a life-threatening disease strongly associated with risk factors such as elevated cholesterol levels, high blood pressure and d ...

    STTR Phase I 2013 Department of Health and Human Services
  9. Selective HDAC1/2 inhibitors for hemoglobinopathies


    DESCRIPTION (provided by applicant): The long term goal of this project is a selective Histone Deacetylase 1 and 2 (HDAC1/2) inhibitor for the treatment of patients with the beta-hemoglobinopathies sickle cell anemia and beta- thalassemia. An estimated 400,000 children are born each year with one of these hemoglobin disorders. Few treatments exist to alleviate the symptoms of hemoglobinopathies an ...

    STTR Phase I 2013 Department of Health and Human Services
  10. A brief iPad-based screening measure for HIV-associated neurocognitive disorders

    SBC: Digital Artefacts LLC            Topic: NIMH

    DESCRIPTION (provided by applicant): HIV-associated neurocognitive disorders (HAND) remain prevalent despite effective anti-retroviral treatments. Cognitive impairments in the current treatment era are often mild and not readily detectable because currentscreening measures (e.g., the HIV Dementia Scale) lack sensitivity to detect subtle impairments in cognitive function. Although more sensitive t ...

    STTR Phase I 2013 Department of Health and Human Services
US Flag An Official Website of the United States Government